Clinical Trials Logo
  1. Home
  2. Ischemic Stroke
  3. NCT05598775
  4. Details
NCT05598775 Clinical Trial

Long-Term Safety Study of CTX0E03 in Subjects Who Completed PISCES III Study

Ischemic Stroke Clinical Trial

— LTFU  

Official title:
Long-Term Safety Study of CTX0E03 in Subjects Who Completed PISCES III Study

Clinical Trial Details — Status: Enrolling by invitation

Administrative data
NCT number NCT05598775
Other study ID # RN01-CP-0004
Secondary ID
Status Enrolling by invitation
Phase
First received
Last updated
Start date November 1, 2022
Est. completion date December 31, 2026

Study information
Verified date October 2022
Source ReNeuron Limited
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this long-term safety study is to follow up subjects treated with CTX0E03 DP to monitor for delayed oncological, neurological, and CTX0E03 DP-related adverse events and to monitor survival

Description:

The goal of this study is to assess the long-term safety of subjects treated with intracerebral CTX0E03 DP as measured by the onset of delayed adverse events of special interest (AESIs). AESIs are defined as adverse events leading to death, new oncological adverse events, new neurological adverse events and any other adverse event, which in the opinion of the Safety/Project Physician is related to CTX0E03 DP.

Recruitment information / eligibility
Status Enrolling by invitation
Enrollment 9
Est. completion date December 31, 2026
Est. primary completion date November 1, 2026
Accepts healthy volunteers
Gender All
Age group 35 Years to 75 Years
Eligibility Inclusion Criteria: Subjects who have received CTX0E03 DP as part of the active arm in the PISCES III study Have provided appropriate written informed consent Exclusion Criteria: - None

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Non Interventional long term safety follow up
Non Interventional long term safety follow up

Locations
Country Name City State
United States Amy Miller, RPh, PharmD Morgantown West Virginia

Sponsors (1)
Lead Sponsor Collaborator
ReNeuron Limited

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Long-term safety study is to follow up subjects treated with CTX0E03 DP Identify delayed oncological, neurological, and CTX0E03 DP-related adverse events and to monitor survival. 4 Years
See also
  Status Clinical Trial Phase
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Completed NCT03281590 - Stroke and Cerebrovascular Diseases Registry
Recruiting NCT05518305 - Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis
Recruiting NCT06029959 - Stroke and CPAP Outcome Study 3 N/A
Recruiting NCT03728738 - Zero Degree Head Positioning in Hyperacute Large Artery Ischemic Stroke Phase 3
Terminated NCT03396419 - IMPACT- 24col Collateral Blood Flow Assessment Following SPG Stimulation in Acute Ischemic Stroke (ImpACT-24B Sub-Study)
Recruiting NCT05065216 - Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) Phase 2/Phase 3
Recruiting NCT04897334 - Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke N/A
Not yet recruiting NCT06462599 - Osteopontin Gene Polymorphism in Stroke Patients in Egypt
Not yet recruiting NCT06032819 - Differentiating Between Brain Hemorrhage and Contrast
Not yet recruiting NCT06026696 - Cohort of Neurovascular Diseases Treated in the Acute Phase and Followed at Lariboisière
Recruiting NCT02910180 - Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders
Completed NCT02922452 - A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects Phase 1
Withdrawn NCT01866189 - Identification of Hypoxic Brain Tissues by F-MISO PET in Acute Ischemic Stroke N/A
Completed NCT03554642 - Walkbot Robotic Training for Improvement in Gait Phase 3
Recruiting NCT03041753 - Reperfusion Injury After Stroke Study N/A
Completed NCT02549846 - AdminiStration of Statin On Acute Ischemic stRoke patienT Trial Phase 4
Completed NCT01678534 - Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial Phase 2
Completed NCT02610803 - Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke N/A